Loading...
Summit Therapeutics posted a larger net loss in Q1 2025 as R&D spending surged due to multiple ongoing Phase III trials for ivonescimab. Despite no revenue, the company maintained a strong cash position and achieved significant clinical milestones.
Summit is progressing with multiple global Phase III trials for ivonescimab and expects topline data from HARMONi mid-2025.
Analyze how earnings announcements historically affect stock price performance